![maxqda v10 two transcript comparison maxqda v10 two transcript comparison](https://windows-cdn.softpedia.com/screenshots/MAXQDA_5.png)
Participants reported the need for strengthening community sensitization for Option B+. There was confusion around dosage and fear of side effects, not having enough food to take drugs, and the lack of opportunities to ask questions in counseling. There was however, a fear of commitment to taking lifelong medication because they were afraid of defaulting, especially after cessation of breastfeeding.
![maxqda v10 two transcript comparison maxqda v10 two transcript comparison](https://i.ytimg.com/vi/inM3_GbgUyI/maxresdefault.jpg)
The majority of women accepted lifelong ART. Resultsįorty-three IDIs, 22 FGDs, and five KIIs were conducted. All interviews were audio-recorded, transcribed, and translated data were coded and analyzed in MaxQDA v10. In-depth interviews (IDIs), focus group discussions (FGDs) and key informant interviews (KIIs) were conducted with PPBW, healthcare providers, and community members. MethodsĪ qualitative study was conducted at selected sites in Harare (urban) and Zvimba (rural) to explore Option B+ acceptability barriers, and facilitators to ART adherence and service uptake. Option B+ was officially launched in Zimbabwe in November 2013 however the acceptability of life-long ART and its potential uptake among women was not known. Zimbabwe’s Ministry of Health and Child Care (MOHCC) adopted 2013 World Health Organization (WHO) prevention of mother-to-child HIV transmission (PMTCT) guidelines recommending initiation of HIV-positive pregnant and breastfeeding women (PPBW) on lifelong antiretroviral treatment (ART) irrespective of clinical stage (Option B+).